Q2 2026 delivered strong revenue growth, led by Afrezza pediatric launch and Furoscix, with marketed products surpassing royalties as the main revenue source. Key product approvals and positive clinical data support continued momentum into the second half of 2026.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.